Comprehensive review of natural and synthetic small molecules—including polyphenols, quinones, alkaloids, metal chelators, osmolytes, and repurposed drugs—that inhibit misfolding and aggregation of amyloid-β, tau, and α-synuclein, with medicinal chemistry and mechanistic discussion.

Valuable for Parkinson's therapeutic discovery because it compiles α‑synuclein‑targeting chemotypes and repurposing candidates and outlines mechanisms useful for hit selection and lead optimization, though it lacks deep clinical/translational validation.

A hallmark of Neurodegenerative Diseases (NDs) is protein misfolding, aggregation, and accumulation in specific brain regions. The accumulation of insoluble, misfolded protein aggregates is usually referred to as amyloid formation. This process leads to cellular dysfunction, destruction of neurons, loss of neuronal connections in specific brain areas, and brain damage. Despite the involvement of distinct pathogenic proteins, the underlying mechanisms of misfolding and aggregate formation are remarkably similar across various NDs. In this review, we present a comprehensive overview of the medicinal chemistry and mechanistic insights into phytochemicals and synthetic small molecules with potential for the treatment of neurodegenerative disorders. Various small molecules have been reported to have therapeutic effects by inhibiting the misfolding, aggregation, and accumulation of pathogenic proteins, such as amyloid-β, tau, and α- synuclein. This review mainly covers natural product-derived small molecules, notably polyphenols (including flavonoids and non-flavonoid polyphenols), as well as other phytochemical classes, such as quinones and alkaloids, along with their possible mechanisms of action. In addition, synthetic small molecules, osmolytes, metal chelators, and repurposed drugs for neurodegenerative disorders are thoroughly discussed.